Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | - | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 6 Years | ||
Fund Size | 1184 Cr | 83 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹200 Lumpsum ₹5000 | ||
Expense Ratio | 0.72% | 1.22% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.79%) Aurobindo Pharma Ltd (7.27%) Cipla Ltd (5.97%) Apollo Hospitals Enterprise Ltd (5.66%) Lupin Ltd (5.2%) | Sun Pharmaceuticals Industries Ltd (10.03%) Piramal Pharma Ltd (5.9%) Torrent Pharmaceuticals Ltd (5.29%) Artemis Medicare Services Ltd Ordinary Shares (5.09%) Glenmark Pharmaceuticals Ltd (4.59%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (97.56%) Basic Materials (2.44%) | Health (93.32%) Basic Materials (6.68%) | ||
Equity % | 95.76% | 98.03% | ||
Debt % | - | - | ||
P/E | 34.41 | 40.52 | ||
P/B | 4.98 | 5.88 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 5.26% | 5.02% | ||
3-Month Return | -3.35% | -2.46% | ||
6-Month Return | -5.96% | -5.54% | ||
1-Year Return | 17.64% | 19.78% | ||
3-Year Return | 20.4% | 16.88% | ||
5-Year Return | 23.98% | 19.64% |
Sharpe | 0.81 | 0.69 | ||
Alpha | 3.47 | -1.35 | ||
Beta | 0.95 | 0.93 | ||
Standard Deviation | 16.85 | 16.51 | ||
Information Ratio | 1.13 | -0.63 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Meeta Shetty | Karan Doshi |